Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Middle cerebral artery peak systolic velocity monitoring of fetal anemia during chemotherapy in pregnancy

A. Babkova, L. Rob, M. Kubecova, M. Hruda, MJ. Halaska

. 2024 ; 103 (4) : 660-668. [pub] 20240116

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24014490

Grantová podpora
Third Medical Faculty, Charles University in Prague

INTRODUCTION: Chemotherapy during pregnancy can increase the risk of fetal anemia. Severe fetal anemia can lead to the development of hydrops fetalis and potentially fetal demise. Hence, it is imperative to implement consistent monitoring methods in the context of chemotherapy treatment. This study aimed to diagnose and monitor fetal anemia using middle cerebral artery peak systolic velocity (MCA-PSV) as a diagnostic tool during chemotherapy in pregnant women. MATERIAL AND METHODS: The study employed a prospective analysis involving a case series of 15 patients diagnosed with cancer during pregnancy and subsequently underwent chemotherapy. MCA-PSV was used to identify fetal anemia. The patients were scheduled for ultrasound examinations of the MCA-PSV. The first examination was performed on the same day as the administration of chemotherapy, while the second occurred on the 10th day after chemotherapy. The measurement technique used in the study was based on the methodology proposed by Mari and Barr. The multiples of the median were calculated using the calculators provided by Medicina Fetal Barcelona. Based on these values anemia severity was determined. When moderate or severe anemia was identified, chemotherapy was individually modified. Additionally, a blood count analysis was conducted immediately after the delivery of the newborn. RESULTS: Five patients were diagnosed with fetal or newborn anemia. With MCA-PSV, we identified moderate fetal anemia in two patients and severe fetal anemia in one. The complete blood count testing of newborns revealed mild anemia in three patients. One case was unrelated to chemotherapy-induced anemia. During treatment, fetal anemia did not corelate with maternal anemia. CONCLUSIONS: In four cases of anemia the combination of cisplatin and iphosphamide was used as a chemotherapy agent. No anemia was observed in other drug combinations. Our findings suggest that MCA-PSV is a reliable method for identifying anemia and should be included in the treatment protocol for chemotherapy-induced fetal anemia.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24014490
003      
CZ-PrNML
005      
20240905133947.0
007      
ta
008      
240725s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1111/aogs.14759 $2 doi
035    __
$a (PubMed)38226422
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Babkova, Anna $u Department of Obstetrics and Gynecology, University Hospital Kralovske Vinohrady, Third Medical Faculty, Charles University in Prague, Prague, Czech Republic $1 https://orcid.org/0009000892686957
245    10
$a Middle cerebral artery peak systolic velocity monitoring of fetal anemia during chemotherapy in pregnancy / $c A. Babkova, L. Rob, M. Kubecova, M. Hruda, MJ. Halaska
520    9_
$a INTRODUCTION: Chemotherapy during pregnancy can increase the risk of fetal anemia. Severe fetal anemia can lead to the development of hydrops fetalis and potentially fetal demise. Hence, it is imperative to implement consistent monitoring methods in the context of chemotherapy treatment. This study aimed to diagnose and monitor fetal anemia using middle cerebral artery peak systolic velocity (MCA-PSV) as a diagnostic tool during chemotherapy in pregnant women. MATERIAL AND METHODS: The study employed a prospective analysis involving a case series of 15 patients diagnosed with cancer during pregnancy and subsequently underwent chemotherapy. MCA-PSV was used to identify fetal anemia. The patients were scheduled for ultrasound examinations of the MCA-PSV. The first examination was performed on the same day as the administration of chemotherapy, while the second occurred on the 10th day after chemotherapy. The measurement technique used in the study was based on the methodology proposed by Mari and Barr. The multiples of the median were calculated using the calculators provided by Medicina Fetal Barcelona. Based on these values anemia severity was determined. When moderate or severe anemia was identified, chemotherapy was individually modified. Additionally, a blood count analysis was conducted immediately after the delivery of the newborn. RESULTS: Five patients were diagnosed with fetal or newborn anemia. With MCA-PSV, we identified moderate fetal anemia in two patients and severe fetal anemia in one. The complete blood count testing of newborns revealed mild anemia in three patients. One case was unrelated to chemotherapy-induced anemia. During treatment, fetal anemia did not corelate with maternal anemia. CONCLUSIONS: In four cases of anemia the combination of cisplatin and iphosphamide was used as a chemotherapy agent. No anemia was observed in other drug combinations. Our findings suggest that MCA-PSV is a reliable method for identifying anemia and should be included in the treatment protocol for chemotherapy-induced fetal anemia.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a novorozenec $7 D007231
650    _2
$a těhotenství $7 D011247
650    _2
$a arteria cerebri media $x diagnostické zobrazování $7 D020768
650    _2
$a rychlost toku krve $7 D001783
650    _2
$a ultrasonografie prenatální $7 D016216
650    12
$a anemie $x chemicky indukované $x diagnóza $7 D000740
650    12
$a nemoci plodu $x chemicky indukované $x diagnostické zobrazování $7 D005315
650    12
$a protinádorové látky $7 D000970
655    _2
$a časopisecké články $7 D016428
700    1_
$a Rob, Lukas $u Department of Obstetrics and Gynecology, University Hospital Kralovske Vinohrady, Third Medical Faculty, Charles University in Prague, Prague, Czech Republic
700    1_
$a Kubecova, Martina $u Department of Oncology, University Hospital Kralovske Vinohrady, Third Medical Faculty, Charles University in Prague, Prague, Czech Republic
700    1_
$a Hruda, Martin $u Department of Obstetrics and Gynecology, University Hospital Kralovske Vinohrady, Third Medical Faculty, Charles University in Prague, Prague, Czech Republic
700    1_
$a Halaska, Michael J $u Department of Obstetrics and Gynecology, University Hospital Kralovske Vinohrady, Third Medical Faculty, Charles University in Prague, Prague, Czech Republic
773    0_
$w MED00009026 $t Acta obstetricia et gynecologica Scandinavica $x 1600-0412 $g Roč. 103, č. 4 (2024), s. 660-668
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38226422 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133941 $b ABA008
999    __
$a ok $b bmc $g 2143942 $s 1226356
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 103 $c 4 $d 660-668 $e 20240116 $i 1600-0412 $m Acta obstetricia et gynecologica Scandinavica $n Acta Obstet Gynecol Scand $x MED00009026
GRA    __
$p Third Medical Faculty, Charles University in Prague
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...